Evaluation of Neopterin as a Neuroinflammatory Marker for Peripheral Neuropathy in Type 2 Diabetic Patients

Israa Abdelmalik Salem; Sura  Ahmed Abdulsattar; Haider Fadhil Alrubaye

doi:10.54133/ajms.v5i1S.397

Authors

Israa Abdelmalik Salem Al-Karama Teaching Hospital, Baghdad, Iraq; Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0009-0005-2890-2529
Sura Ahmed Abdulsattar Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0002-4707-7799
Haider Fadhil Alrubaye Department of Internal Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0002-3912-8103

DOI:

https://doi.org/10.54133/ajms.v5i1S.397

Keywords:

Diabetes Mellitus; Peripheral Neuropathy; Inflammation; Nerve Conduction Study; Michigan Neuropathy Screening Instrument; Neopterin.

Abstract

Background: Elevation of the marker neopterin is associated with the progression and consequences of diabetes. Although the clinical relationship between the high levels and peripheral neuropathies other than diabetic peripheral neuropathy is unknown, it has been linked to them. Objective: To evaluate the difference in serum neopterin levels between diabetic individuals who have peripheral neuropathy and those who do not. Methods: This seven-month cross-sectional study at the Diabetic Center began in December 2022 and included 126 patients with the second type of diabetes mellitus. Following verbal consent, the included patients were subjected to neurological and physical evaluations. Along with the blood pressure, the weight and height were noted. Glucose, TG, CH, HDL-c, fasting insulin, and neopterin were all analyzed using serum. Formulas were used to compute BMI, LDL-c, and VLDC. Results: When diabetic individuals with peripheral neuropathy were compared to those without, the serum levels of neopterin in the former group revealed a marginally higher level than in the latter, but this difference was not statistically significant. Conclusion: Neopterin levels were not altered in diabetic individuals with peripheral neuropathy, indicating that it is not a reliable indicator of the condition.

Downloads

Download data is not yet available.

References

Kasznicki J, Kosmalski M, Sliwinska A, Mrowicka M, Stanczyk M, Majsterek I, et al. Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep. 2012;39(9):8669–8678. doi: 10.1007/s11033-012-1722-9.

Arora K, Tomar PC, Mohan V. Diabetic neuropathy: an insight on the transition from synthetic drugs to herbal therapies. J Diabetes Metab Disord. 2021;20(2):1773–1784. doi: 10.1007/s40200-021-00830-2.

Xue T, Zhang X, Xing Y, Liu S, Zhang L, Wang X, et al. Advances about immunoinflammatory pathogenesis and treatment in diabetic peripheral neuropathy. Front Pharmacol. 2021;12:1–10. doi: 10.3389/fphar.2021.748193.

Robertson J, Gostner JM, Nilsson S, Andersson LM, Fuchs D, Gisslen M. Serum neopterin levels in relation to mild and severe COVID-19. BMC Infect Dis. 2020;20 doi: 10.1186/s12879-020-05671-7.

Tezcan D, Onmaz DE, Sivrikaya A, Hakbilen S, Körez MK, Gülcemal S, et al. Assessment of serum resistin and calprotectin as biomarkers for subclincial inflammation in patients with familial Mediterranean fever. Mediterr J Rheumatol. 2022;33(3):322–327. doi: 10.31138/mjr.33.3.322.

Baxter-Parker G, Roffe L, Cross S, Frampton C, Hooper GJ, Gieseg SP. Knee replacement surgery significantly elevates the urinary inflammatory biomarkers neopterin and 7,8-dihydroneopterin. Clin Biochem. 2019;63:39–45. doi: 10.1016/j.clinbiochem.2018.11.002.

Gürcü S, Girgin G, Yorulmaz G, Kılıçarslan B, Efe B, Baydar T. Neopterin and biopterin levels and tryptophan degradation in patients with diabetes. Sci Rep. 2020;10(1):1–8. doi: 10.1038/s41598-020-74183-w.

Kember I, Sanajou S, Kilicarslan B, Girgin G, Baydar T. Evaluation of neopterin levels and kynurenine pathway in patients with acute coronary syndrome. Acute Crit Care. 2023;38(3):325–332. doi: 10.4266/acc.2023.00024.

Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther. 2001;26(5):319–329. doi: 10.1046/j.1365-2710.2001.00358. x.

Pingle S, Tumane R, Jawade A. Neopterin: Biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseases. Indian J Occup Environ Med. 2008;12(3):107–111. doi: 10.4103/0019-5278.44690.

Dogheim GM, Amralla MT, Werida RH. Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level. Inflammopharmacology. 2022;30(5):1617–1622. doi: 10.1007/s10787-022-01028-5.

Lee JE, Oh TJ, Moon JH, Park KS, Jang HC, Choi SH. Serum neopterin concentration and impaired glucose metabolism: Relationship with β-cell function and insulin resistance. Front Endocrinol. 2019;10:1–6. doi: 10.3389/fendo.2019.00043.

Elbarbary NS, Ismail EAR, El-Hilaly RA, Ahmed FS. Role of neopterin as a biochemical marker for peripheral neuropathy in pediatric patients with type 1 diabetes: Relation to nerve conduction studies. Int Immunopharmacol. 2018;59:68–75. doi: 10.1016/j.intimp.2018.03.026.

Ghafouri B, Thordeman K, Hadjikani R, Bay Nord A, Gerdle B, Bäckryd E. An investigation of metabolome in blood in patients with chronic peripheral, posttraumatic/postsurgical neuropathic pain. Sci Rep. 2022;12(1):1–8. doi: 10.1038/s41598-022-26405-6.

Shyma RL, Mini S. Neuroprotective effect of Morin via TrkB/Akt pathway against diabetes mediated oxidative stress and apoptosis in neuronal cells. Toxicol Mech Methods. 2022;32(9):695–704. doi: 10.1080/15376516.2022.2065225.

Yan J, Kothur K, Mohammad S, Chung J, Patel S, Jones HF, et al. CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation. EBioMedicine. 2023;91:1–13. doi: 10.1016/j.ebiom.2023.104589.

Eichwald T, da Silva B, Staats-Pires AC, Niero L, Schnorrenberger E, Filho CC, et al. Tetrahydrobiopterin: Beyond its traditional role as a cofactor. Antioxidants. 2023;12(5):1–27. doi: 10.3390/antiox12051037.

Mitteer DR, Greer BD. Using GraphPad Prism’s heat maps for efficient, fine-grained analyses of single-case data. Behav Anal Pract. 2022;15(2):505–514. doi: 10.1007/s40617-021-00664-7.

Vaeggemose M, Pham M, Ringgaard S, Tankisi H, Ejskjaer N, Heiland S, et al. Magnetic resonance neurography visualizes abnormalities in sciatic and tibial nerves in patients with type 1 diabetes and neuropathy. Diabetes. 2017;66(7):1779–1788. doi: 10.2337/db16-1049.

Lv Y, Yao X, Li X, Ouyang Y, Fan C, Qian Y. Cell metabolism pathways involved in the pathophysiological changes of diabetic peripheral neuropathy. Neural Regen Res. 2024;19(3):598–605. doi: 10.4103/1673-5374.380872.

Msheik Z. Central and peripheral neuroinflammation: A focus on the macrophage. In: Immunology and Cancer Biology. 2023. p. 1–43. Available from: www.videleaf.com

Ünüvar S, Tanrlverdi Z, Aslanhan H. Potential prognostic role of immune system activation marker neopterin in patients with type 2 diabetes. J Med Biochem. 2018;37(4):465–469. doi: 10.2478/jomb-2018-0004.

Casadei G, Filippini M, Brognara L. Glycated hemoglobin (HbA1c) as a biomarker for diabetic Foot peripheral neuropathy. Diseases. 2021;9(1):16. doi: 10.3390/diseases9010016.

Dhillon S, Fith A, Batubara CA. The association between wasit hip and severity of diabetic peripheral neuropathy in diabetes mellitus type 2 by using Toronto Clinical Scoring System. J Sco Med. 2023;2(4):107–116. doi: 10.1016/j.agrformet.2007.11.012.

Mansour AA. Chronic complications of diabetes in Iraq: Experience from Southern Iraq. Clin Med Insights Endocrinol Diabetes. 2009;2:89–97. doi: 10.4137/cmed.s3657.

Melicharova K, Kusalova M, Smahelova A, Hyspler R, Solichova D, Melichar B. Urinary neopterin in patients with diabetes mellitus and foot ulcers. Pteridines. 2007;18(4):128–131. doi: 10.1515/pteridines.2007.18.1.128.

Sempere-Bigorra M, Julián-Rochina I, Cauli O. Differences and similarities in neuropathy in type 1 and 2 diabetes: A systematic review. J Pers Med. 2021;11(3):1–20. doi: 10.3390/jpm11030230.

Jende JME, Groener JB, Oikonomou D, Heiland S, Kopf S, Pham M, et al. Diabetic neuropathy differs between type 1 and type 2 diabetes: Insights from magnetic resonance neurography. Ann Neurol. 2018;83(3):588–598. doi: 10.1002/ana.25182.

Ebadi SA, Tabeie F, Tavakoli S, Khalili S. Effects of photo biomodulation with two wavelengths of 630 and 810 nm on diabetic neuropathy. J Lasers Med Sci. 2023;14(1):10–14. doi: 10.34172/jlms.2023.22.

Feingold KR, Grunfeld C. Effect of inflammation on HDL structure and function. Curr Opin Lipidol. 2016;27(5):521–530. doi: 10.1097/MOL.0000000000000333.

Martagon AJ, Zubirán R, González-Arellanes R, Praget-Bracamontes S, Rivera-Alcántara JA, Aguilar-Salinas CA. HDL abnormalities in type 2 diabetes: Clinical implications. Atherosclerosis. 2023;117213:1–8. doi: 10.1016/j.atherosclerosis.2023.117213.

Sasso FC, Pafundi PC, Gelso A, Bono V, Costagliola C, Marfella R, et al. High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. Diabetes Res Clin Pract. 2019;150(2019):236–244. doi: 10.1016/j.diabres.2019.03.028.